ADMA Biologics Inc vs iShares Global Clean Energy ETF — how do they compare? ADMA Biologics Inc trades at $9.93 (market cap $2.22B), while iShares Global Clean Energy ETF trades at $18.47. The key difference: iShares Global Clean Energy ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ICLN | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $23.75 |
52-Week Low | $7.60 | $13.66 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
ICLN trades at $18.69, up 3.37% today, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces headwinds from higher expense ratios compared to traditional energy peers and regulatory uncertainty around renewable energy permits. Recent news highlights clean energy's 25% gains in 2026 but notes volatility concerns versus fossil fuel alternatives.
The outlook remains cautious as policy risks and competitive pressure from lower-cost energy ETFs challenge near-term performance. Long-term growth potential exists from global clean energy adoption, but investors face volatility and fee disadvantages relative to traditional energy funds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →